Compare Live Nation Entertainment, Inc. (LYV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Novo Nordisk A/S — how do they compare? Live Nation Entertainment, Inc. trades at $180.98 (market cap $42.09B), while Novo Nordisk A/S trades at $49.29 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 5.2× Live Nation Entertainment, Inc.'s market cap, and Novo Nordisk A/S pays a 3.63% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | NVO | |
|---|---|---|
Market Cap | $42.09B | $220.53B |
Sector | Industrials | Health |
52-Week High | $186.59 | $71.70 |
52-Week Low | $125.61 | $35.29 |
Enterprise Value | $43.59B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
